Cite
HARVARD Citation
Gürbüz, M. et al. (2022). Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group. Medicine. 101 (50), pp. e32368-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Gürbüz, M. et al. (2022). Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group. Medicine. 101 (50), pp. e32368-. [Online].